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Five cloned human hepatic UDP-glucuronosyltransferase (UGT) cDNAs were stably expressed in tissue culture cell lines. More than 100 drugs and
xenobiotics were used as substrates for glucuronidation catalyzed by the cloned human transferases to determine the chemical structures accepted
as substrates. UGT-HP1 exhibited a limited substrate specificity for planar phenolic compounds, whereas UGT-HP4 was more accepting of
nonplanar phenols, anthraquinones, flavones, alphatic alcohols, aromatic carboxylic acids, steroids and many drugs of varied structure. UGT-HP3
(bilirubin UGT) catalyzed the glucuronidation of ethinylestradiol. UGT-H6 and UGT-H25 (steroid/bile acid UGTs) also catalyzed the glucuronidation of
some xenobiotics. Levels of UGT-HP4 activity towards some substrates were sufficient to allow determination of kinetic parameters for the enzyme
reaction. Further, metabolism of drugs could be studied by addition to the recombinant cell lines in culture and extraction of the media allowed
analysis of glucuronide formation. The protection afforded against cytotoxic drugs was observed. The data presented here demonstrate the potential
of using these recombinant cell lines for investigation of phase 11 metabolism by human UGTs and subtle differences in protein structure which
affect their specificity. -Environ Health Perspect 102(Suppl 9):19-23 (1994)
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Introduction
Numerous drugs and xenobiotics are
excreted as glucuronide conjugates. For
many of these compounds, glucuronida-
tion is the major route ofdetoxication and
safe elimination (1,2).
The important feature of human glu-
curonidation is that identical systems may
not exist in common laboratory species,
such as the ability to form quaternary
ammonium glucuronides of tertiary amine
drugs (2). Inaccessibility to humans and
their tissues for experimentation has
severely restricted studies of drug glu-
curonidation systems and the use of this
knowledge for drug discovery.
This article was presented at the IV European ISSX
Meeting on Toxicological Evaluation of Chemical
Interactions: Relevance of Social, Environmental and
Occupational Factors held 3-6 July 1992 in Bologna,
Italy.
The authors wish to thank The Wellcome Trust,
The Medical Research Council, The Scottish Home
and Health Department and The Cancer Research
Campaign for grants supporting this work. Thomas
Ebner was supported by the Robert Bosche
Foundation, Stuttgart; Sehidan bin Senafi was sup-
ported by the National University of Malaysia.
Address correspondence to Dr. Brian Burchell,
Department of Biochemical Medicine, Nimewells
Medical School, University of Dundee, DD1 9SY,
Scotland. Telephone 44 0382 60111, ext. 2164. Fax
44 0382 644620.
Therefore, alternative systems, which
attempt to mimic human glucuronidation
need to be devised. We have developed
the use of recombinant cell lines express-
ing human UGTs to facilitate the study of
the biochemistry of glucuronidation in
physiological systems. These systems have
great potential for our understanding of
the specificity of human glucuronidation,




The UGTs are a group of isoenzymes of
50-60 kDa localized primarily in hepatic
endoplasmic reticulum and nuclear enve-
lope (3). The UGT superfamily (4) has
evolved to catalyze the glucuronidation of
potentially toxic endobiotics and ancient
environmental xenobiotics, thereby facili-
tating transport and excretion of more
water-soluble glucuronides. The glu-
curonidation of drugs by this system is
probably fortuitous as the pace of the
chemical revolution has easily overtaken
biological evolution. The expression of
UGTs is differentially regulated by xenobi-
otic and hormonal inducers and during
development, such that different tissue spe-
cific profiles ofactivities are observed (5).
A nomenclature for the UDP-glu-
curonosyltransferase superfamily has been
proposed, based on divergent evolution of
the genes (4). A total of26 distinct cDNAs
in five mammalian species have been
cloned and sequenced to date. Comparison
ofdeduced amino acid sequences has lead
to the definition oftwo families and a total
ofthree subfamilies.
Nine human liver UGT cDNAs have
recently been cloned and two subfamilies
have been classified by sequence identities
(6). Subfamily 1 consists of at least four
UGTs that catalyze the glucuronidation of
xenobiotic phenols and bilirubin (7,8), but
not some steroids or bile acids. Interest-
ingly, these four cDNAs encoding UGTs
share identical C-terminal 246 amino acid
residue sequences, but variable N-terminal
285 amino acid residue sequences.
Construction of hybrid proteins (9)
and comparative sequence analysis of
UGTs (5) suggest the substrate binding
specificity is provided by the N-terminal
halfofproteins and that UDP-glucuronic
acid binds in the C-terminal portion prob-
ably involving key amino acids between
residues 350 and 400.
Evidence from Southern-blot analysis
indicates that there is only one copy ofthe
conserved 3' region of the UGT1 gene in
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the human genome. Chromosomal map-
ping of the sequences encoding the four
variable regions using specific probes indi-
cated that all of these sequences were
located on human chromosome 2 (10,11).
These results suggest that at least four
isoenzymes may be derived from variable
exons and conserved exons within the same
gene. The above studies have been authen-
ticated by the work of Ritter et al. (12).
They have reported the isolation offour
human cosmid clones that span 110 kb
and contain the four constant 3' exons on
the phenol/bilirubin UGTs. Moreover
these genomic clones contain sixvariable 5'
exons that include the coding sequence for
HP1, HUGBrl, and HUGBr2 as well as
three other UGT coding exons. It has been
proposed that these UGT mRNAs result
from alternative splicing from this gene
complex. Subfamily 2 contains at least five
UGTs catalyzing steroid or bile acid glu-
curonidation (13-15). Subfamily 2
appears to consist ofseveral separate genes
each encoding a unique steroid UGT while
retaining a similar gene structure even in
different species (16,17). These genes
appear to be localized in a cluster on chro-
mosome 4 (17).
The analysis ofthe structural features of
UGTs and the proteolytic/immunochemi-
cal analysis of proteins in the ER mem-
brane (18,19) has provided insights into
the transverse topology of these enzymes.
These studies suggest that the major por-
tion of the proteins (including the active
sites) reside within the lumen of the ER
membrane and that the protein is retained
in this organelle by a C-terminal mem-
brane spanning region and a charged
cytosolic retention signal peptide (3).
The proteins are synthesized and
inserted into endoplasmic reticulum using
a series ofsignal sequences. An N-terminal
signal peptide (approximately 23AA
residues), which is subsequently removed
(3), targets the protein into the ER mem-
brane; charged C-terminal lysines and a
membrane spanning region establish reten-
tion and orientation in the membrane
(20,21). This general structure may be fur-
ther stabilized by the known glycosylation
ofthe UGTs (3).
This UGT localization in microsomal
membranes embraces the concept oflatent
enzyme activities. Microsomal UGTs are
activated up to 20-fold by detergent dis-
ruption or proposed physiological activa-
tors such as UDP-N-acetylglucosamine
(22). The lumenal compartmentalization
of UGT activities within the ER creates a
barrier for substrate and UDP-glucuronic
acid access to the active site invoking a pos-
sible need for transporters assisting in glu-
curonidation (23).
Therefore, the use of recombinant cell
lines expressing UGTs to duplicate and
facilitate understanding ofthe physiologi-
cal systems should consider orientation of
UGTs into ER. Fortunately, biological
evolution has allowed development ofboth
consistent and versatile mechanisms, which
facilitate experimental creation ofartificial
but functional cell systems.
Here we describe how cloned expressed
UGT isoenzymes have been used to study
drug glucuronidation and the potential
role of glucuronidation in protection of
cells against cytotoxic agents.
Methods
CloningandStableTransfctionof
UGTs intoThsue Culture Cells
Human liver cDNA libraries in various
bacteriophage expression vectors were
screened with several nucleic acid probes.
The protocols used to screen the libraries
and obtain full length clones, have been
described in detail elsewhere (6,7).
The UGT cDNAs were subcloned into
the eukaryotic expression vector pcDNAneo.
Linearized recombinant plasmid DNA was
introduced into Chinese hamster V79 lung
fibroblasts facilitated by the transfection
reagent DOTAP. Stably transfected
colonies (G418-resistant) were isolated and
cultured as previously described (24).
Analysis ofThsue Culture Cell
Homogenates andHuman Liver
Microsomes
UGT-V79 cells were washed twice with
PBS and gently homogenized (24).
Human liver microsomal fractions were
prepared as described (25). SDS polyacry-
lamide gel electrophoresis andWestern blot-
ting ofhomogenates and microsomes were
performed as previouslydescribed (7).
Assay of UGT activities in cell homo-
genates was determined by TLC assay
using 0.5 mM substrate and 2 mM
UDPGA (including [14C] 2pCi labeled
UDPGA) (26). Bilirubin UGT activity
was determined as previously described
(27). Protein levels were assayed by the
Lowry method (28).
ChemosensitivityTesting
UGT-recombinant cell lines were seeded
into 24 well plates at 1000 cells/well to
allowexponential growth during the course
ofthe assay (4 days). Cells were grown in
DMEM supplemented with 10% fetal calf
serum, 2 mm glutamine and 100 U/ml
penicillin/streptomycin and maintained in
a humidified atmosphere of5% C02-95%
air at 37°C. Cytotoxic drugs were added in
a range ofconcentrations from 10 x stock
solutions to cells for 2 days. A viable cell




UGTs inV79 Cell Lines
Immunochemical analysis ofhomogenates
of cell lines showed the presence of high
levels ofexpressed enzymes UGT1 subfam-
ily, UGT-HP1 (Mr 55 kDa), UGT-HP3
(Mr 55.5 kDa), and UGT-HP4 (Mr 56
kDa) (6,30). Further immunochemical
analysis ofwhole cells has revealed the
localization of the enzymes in the endo-
plasmic reticulum and nuclear envelope
(24). The UGTlA1 (HP1) expressed in
cell cultures has been demonstrated to be a
latent glycosylated enzyme suggesting the
correct insertion and orientation ofUGT
in the microsomal membranes (Pritchard,





This gene subfamily has at least four
known expressed isoenzymes derived from
the same gene (12), where cloned cDNAs
have been used to study the substrate speci-
ficity of the isoenzymes. Two of these
isoenzymes (HP2 and HP3) appear to be
specifically responsible for catalyzing
bilirubin glucuronidation (8,30), and
UGT-HP1, and UGT-HP4 catalyze glu-
curonidation of simple or bulky phenols
respectively (7,26,31). The substrate speci-
ficity ofthese enzymes is now being exten-
sively studied and all the isoenzymes are
able to catalyze the glucuronidation of
some xenobiotic chemicals. A selection of
the results from our published work are
summarized in Table 1.
The difference between the two
expressed phenol UGTs (HP1 and HP4) is
their ability to glucuronidate phenols sub-
stituted with increasingly bulky alkyl
groups. The transferase encoded by UGT-
HP1 exhibits a high activity towards planar
phenols such as 1-naphthol, 4-methylphe-
nol, and 4-ethylphenol. However,
expressed UGT-HP4 shows a high activity
towards 4-propylphenols, 4-butylphenols
and pentylphenols, and 4-hydroxy-
biphenyl; whereas little or no activity was
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Abbreviations -, notassayed; ND, not detected.
detected using UGT-HP1. This remark-
able difference suggests that structural dif-
ferences within the active sites ofthe two
enzymes limit the dimensions ofsubstrate
accepted by UGT-HP1. This transferase
will accept benzo[a]pyrene-3, 6-quinol and
performed better with 1-naphthol as sub-
strate (32), and therefore the planarity of
the substrate accepted seems to be a most
important criterion.
However, it is apparent that two
enzymes may be involved in the metabo-
lism of a single substrate as demonstrated
by biphasic kinetics of microsomal glu-
curonidation. Their individual performance
may be dependent on the concentration of
the aglycone. Paracetamol is glucuronidated
by both UGTs HP1 and HP4; but HP1
has an apparent Km of 2.5 mm, whereas
HP4 exhibited an apparent Km of 50 mm
(33). The results would suggest that UGT-
HP1 is the high affinity paracetamol glu-
curonidating enzyme in man.
Our work has demonstrated that UGT-
HP4 is capable of catalyzing the glu-
curonidation ofawider range ofcompounds
in terms of the general structure and the
functional group which is glucuronidated.
High levels oftransferase activity for com-
pounds with phenolic-OH groups such as
the anaesthetic propofol (2,6-diisopropyl
phenol) and also several phenols ofplant
origin such as thymol, carvacrol, and
eugenol were observed. The latter two
compounds are also glucuronidated by the
UGT-HP1 isoenzyme whereas only
minute amounts of the glucuronides of
thymol and no glucuronides ofpropofol
were formed by UGT-HP1. This is proba-
bly due to the bulky isopropyl substituents
in position 2 to the phenolic OH-group
(thymol is 2-isopropyl-5-methylphenol).
UGT-HP4 also showed activity for the glu-
curonidation ofterpenoids with aliphatic
OH groups such as carveol, citronellol,
nopol and sipinocapheol. Surprisingly, car-
boxylic acids (substituted propionic acids
used as nonsteroidal antiinflammatory
drugs like ibuprofen, fenoprofen,or
naproxen) were also substrates for this
enzyme. The ability ofUGT-HP4 to glu-
curonidate bulkier, more complex mole-
cules is also reflected in the formation of
glucuronides of fluorescein, phenol-
phthalein, anthraquinones (such as
emodin), and flavones (such as quercetin).
UGT-HP4 catalyzed the glucuronida-
tion offood preservatives, e.g., esters of4-
hydroxybenzoic acid and vanillin and also
N-glucuronidation of dapsone. This
human transferase is apparently a key
enzyme in the detoxication of many xeno-
biotic compounds and drugs (26). Neither
of the cloned, expressed UGTs catalyzed
the glucuronidation of (-) morphine,
estriol, or androsterone, although high
activity of UGT-HP4 towards 4-OH-
estrone was observed. The more suitable
endogenous or xenobiotic substrates may
remain to be identified.
The bilirubin UGT (HP3) was a poor
catalyst ofmost substrates tested (Table 1),
although ethinylestradiol was a good sub-
strate for this enzyme and further kinetic
analysis of human liver microsomes has
indicated that bilirubin UGT may be
responsible for catalyzing ethinylestradiol




The first full-length human liver UGT
cDNA (H25) was published by Jackson et
al. (34). The derived protein sequence
exhibits an identity of64% to the sequence
derived from the rat liver UGT cDNA
Rlug38, testosterone UGT (35). Subse-
quently, UGT-H25 was expressed in cell
cultures and determined to catalyze the
glucuronidation of hyodeoxycholic acid
but not xenobiotics (13,24). Recently,
Ritter et al. (12) have shown that this
enzyme also catalyzed the glucuronidation
ofestriol and 4-hydroxyesterone. Jackson
screened a human liver cDNA library with
UGT-H25 at low stringency. He isolated
three additional UGT cDNAs, H4, H7,
and H32. The identity between these
human UGT cDNA clones varied from 66
to 75%. However, only UGT-H25 was full
length. Therefore, another human liver
cDNA library was screened with UGT-
H25. This identified six putative positives,
including UGT-H14 and UGT-H6.
Ritter et al. (37) published the
sequence of human liver UGT cDNA,
UDP-GTh2, that has an identity of 96%
when compare to UGT-H6. The high
identity between UGT-H6 and UDP-
GTh2 indicates that these two cDNAs may
be derived from different alleles ofthe same
gene.
When expressed in cell cultures both of
these enzymes primarily catalyze the glu-
curonidation ofestrogens. Ritter et al. (37)
tested this transferase with some 20 xenobi-
otic substrates and no detectable glu-
curonides were formed. Although another
very similar expressed cloned UGT has
been shown to slowly catalyze the glu-
curonidation ofcarboxylic acid drugs such
as clofibrate, valproate, naproxen, fenopro-
fen, and zomepirac, although quantitative
data have notyet been reported (38).
Burchell et al. (4) have proposed that
any two UGT cDNAs with less than 97%
identity are derived from different genes.
Nebert and Gonzalez (39) arbitrarily assign
P450 cDNAs as being derived from differ-
ent mRNAs and different genes when their
identity is >97% but where functional dif-
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ferences have been shown. Nebert and
Gonzalez (39) do not allow for cDNAs
that have identities of <97% that show
functional similarities. Although UGT-H6
and UDP-GTh2 do have similar catalytic
properties, the coding sequence for UDP-
GTh2 is six bases longer and 50 other base
changes were observed, introducing some
charge differences to the sequence (40).
With these base changes and the cut-off
point for the P450 genes, it is proposed
that UGT-H6 and UDP-GTh2 are derived
from different genes. This proposal will
only be proven by the isolation of further
human UGT cDNAs or from the isolation
ofthe genes encoding these isoforms.
AssessmentofResistance toXenobiotic
andAnticancerDrug-inducedToxicity
in Recombinant ll ines Stably
ExpressingHuman UGTs
In a preliminary experiment, UGT-HP1
stably expressed in NlH-3T3 cells was
shown to enhance cell survival 10-fold
against mitoxanthrone, when compared to
nontransfected 3T3 cells (41). Similar
results have been demonstrated using other
expressed UGTs and cytotoxic drugs.
Figure 1 shows that stably expressed UGT-
HP4 (a phenol UGT) enhanced cell sur-
vival 5- to 10-fold against doxorubicin.
The additional protection against these
cytotoxic anticancer drugs is presumably
caused by an increased rate ofglucuronida-
tion and facilitated excretion ofthese com-
pounds. Indeed, doxorubicin was also
shown to be glucuronidated by human
Doxorubicin
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Figure 1. Cellular protection against doxorubicin toxicity is increased by an expressed human liver UGT-HP4.
Chinese hamster lung fibroblast V79 cells and V79 cells stably transfected with UGT-HP4 were exposed to increas-
ing concentrations of doxorubicin. ---, V79 cells; -a-, V79/HP4 cells.
liver microsomal preparations (unpublished
data).
Conclusions
Clearly there is enormous potential of
cloned human UGTs expressed in tissue
culture cells in the study of drug glu-
curonidation. Several cloned transferases
stably expressed in cell lines are already
available. Additional cloned UGTs will
become available in the near future.
Therefore, we should be in a position to
examine the abilities ofthese cloned trans-
ferases to catalyze the glucuronidation of
therapeutically important drugs and assess
the potential dangers ofpolymorphic varia-
tion of UGTs in routine drug treatments.
Further, the important role of UGTs in
cellular defense against cytotoxic chemicals
has been clearly demonstrated, indicating
the value ofthese cell lines in defining this
role.
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